Prakash Gowd

Billionaire investor Bill Ackman cut his losses in Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s stock so now is the time for both the company and hedge fund manager to move on. According to a Bloomberg report, Valeant's path forward is difficult and characterized by the company having less money...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is reportedly shopping for buyers to acquire its Salix unit for an expected $8.5 billion and additional royalty payments in the future. Valeant is plagued with debt, causing some concern among shareholders so any cash infusion would certainly ease...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) recently held its Investor Day, where management provided revised guidance, in line with estimates. Following the event, CIBC analysts Prakash Gowd and Ryan Lee issued a Sector Perform rating and $90 price target on the shares. The experts commented...